Co-Diagnostics Inc. (CODX)
NASDAQ: CODX
· Real-Time Price · USD
0.36
0.01 (2.56%)
At close: May 01, 2025, 3:59 PM
0.36
0.03%
After-hours: May 01, 2025, 04:05 PM EDT
Co-Diagnostics Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|
| Grant Revenue Revenue | 434.26K | 215.11K | 854.94K | 136.53K |
| Grant Revenue Revenue Growth | +101.88% | -74.84% | +526.18% | n/a |
| Product Revenue Revenue | 206.88K | 252.75K | n/a | n/a |
| Product Revenue Revenue Growth | -18.15% | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|
| Rest Of World Revenue | 331.86K | 9.55M | 45.7M | 29.69M |
| Rest Of World Revenue Growth | -96.52% | -79.11% | +53.92% | n/a |
| United States Revenue | 659.62K | 24.67M | n/a | n/a |
| United States Revenue Growth | -97.33% | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 5.35M | 4.17M | 4.48M | 5.92M | 5.05M | 5.45M | 4.72M | 6.58M | 5.51M | 3.94M | 5.57M | 5.32M | 7.17M | 8.32M | 4.13M | 5.63M | 3M | 2.58M | 1.73M | 1.28M | 1.32M | 1.06M | 896.47K | 1.44M | 1.33M | 992.56K | 977.31K | 1.2M | 1.52M | 507.15K | 289.95K | 244.9K | 212.25K | 209.32K | 252.53K | 251.5K |
| Selling, General, and Administrative Revenue Growth | +28.12% | -6.89% | -24.29% | +17.20% | -7.25% | +15.39% | -28.27% | +19.38% | +39.88% | -29.31% | +4.76% | -25.82% | -13.81% | +101.34% | -26.62% | +87.64% | +16.30% | +49.38% | +35.05% | -3.30% | +24.84% | +18.22% | -37.58% | +7.94% | +34.04% | +1.56% | -18.72% | -21.05% | +200.31% | +74.91% | +18.40% | +15.38% | +1.40% | -17.11% | +0.41% | n/a |
| Research and Development Revenue | 4.88M | 5.61M | 5.68M | 6.18M | 5.79M | 5.98M | 5.01M | 4.74M | 5.04M | 3.89M | 3.77M | 2.18M | 5.89M | 4.67M | 2.22M | 1.11M | 921.89K | 750.25K | 400.02K | 380.51K | 331.03K | 312.59K | 347.31K | 375.43K | 330.42K | 357.89K | 297.42K | 281.39K | 272.21K | 184.88K | 264.69K | 191.66K | 172.8K | 172.11K | 194.91K | 194.12K |
| Research and Development Revenue Growth | -13.05% | -1.18% | -8.08% | +6.74% | -3.21% | +19.29% | +5.79% | -5.92% | +29.50% | +3.14% | +72.81% | -62.97% | +26.22% | +110.60% | +99.17% | +20.74% | +22.88% | +87.55% | +5.13% | +14.95% | +5.90% | -10.00% | -7.49% | +13.62% | -7.67% | +20.33% | +5.69% | +3.37% | +47.24% | -30.15% | +38.11% | +10.91% | +0.40% | -11.70% | +0.41% | n/a |
| Sales and Marketing Revenue | 1.06M | 1.04M | 1.56M | 1.52M | 1.9M | 1.73M | 1.71M | 1.33M | 1.89M | 1.47M | 2.65M | 2.09M | 4.25M | 5.85M | 1.2M | 3.21M | 798.47K | 390.19K | 268.48K | 291.14K | 262.36K | 252.08K | 256.1K | 746.22K | 180.26K | 143.89K | 95.26K | 119.79K | 117.08K | 125.63K | 64.22K | 45.51K | 28.89K | 22.42K | 25.29K | 47.56K |
| Sales and Marketing Revenue Growth | +1.78% | -33.41% | +3.07% | -20.34% | +9.89% | +1.56% | +28.26% | -29.61% | +28.37% | -44.49% | +26.66% | -50.77% | -27.34% | +388.78% | -62.67% | +301.76% | +104.64% | +45.33% | -7.78% | +10.97% | +4.08% | -1.57% | -65.68% | +313.98% | +25.27% | +51.05% | -20.47% | +2.32% | -6.80% | +95.63% | +41.12% | +57.51% | +28.86% | -11.36% | -46.83% | n/a |